Survey of Over 1,000 Asthma and COPD Patients
Conducted in Partnership with AAFA Finds Symptoms are Disruptive to
Daily Lives for Majority of Respondents Despite Treatment
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical
Industries Ltd. (NYSE and TASE: TEVA), today announced the launch
of Inhaler Tales – a national campaign aimed at raising awareness
about the role inhaler misuse may play in inadequate disease
Central to the campaign is an animated inhaler voiced by
actress, producer, and entrepreneur Sarah Michelle Gellar, who will
share her own experience living with asthma and encourage others to
take control of their disease.
“I was diagnosed with asthma when I was a kid, so I know the
impact respiratory disease can have on your life,” says Gellar.
“I’m proud to join forces with Teva to launch this important
campaign, and to raise awareness about improper inhaler use and the
role of objective inhaler use data in informing dialogue between
patients and their physicians.”
Respiratory disease can impact your daily life2 if inadequately
controlled, and a common problem is inhaler misuse.3 According to a
survey of more than 1,000 asthma and chronic obstructive pulmonary
disease (COPD) patients conducted by Teva in partnership with the
Asthma and Allergy Foundation of America (AAFA), 40% of asthma and
COPD patients feel that their conditions get in the way of their
lives because they are short of breath.4 The same survey found that
the majority of respondents feel confident that they’re using their
inhaler correctly, but a substantial proportion may not be using
their inhaler as prescribed.5
“Patients want to get their asthma and COPD under control6,7 but
they may not realize that poor adherence or incorrect inhaler
technique8 could be contributing to worsening symptoms,” said Sanaz
Eftekhari, Vice President of Research at AAFA. “This survey
revealed that only 45 percent of respondents report using their
maintenance inhaler exactly as prescribed9, and more than 50% may
be overusing their rescue inhaler10, which may lead to exacerbation
risk.11,12 This campaign will play an important role in raising
overall awareness about this issue, and call attention to the
importance of open dialogue13 between physicians and their
As of 2019, the Centers for Disease Control and Prevention
reported 20 million adults were affected by asthma14, and another
16 million struggle with COPD.15 Although these respiratory
diseases are common, many patients’ asthma or COPD is still
uncontrolled.16,17 A variety of factors may lead to inadequate
disease control18 and patients often do not realize that they may
be unintentionally19 contributing to the problem by not using their
inhalers correctly.20 While patients may be experiencing these
issues, healthcare professionals may not always get the chance to
review inhaler use and technique with their patients as often as
recommended.21 Survey findings revealed that a third of respondents
forget what they want to discuss when they visit their
For more information about digital health options23, including
smart inhalers24, please visit InhalerTales.com.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements. You
can identify these forward-looking statements by the use of words
such as “should,” “expect,” “anticipate,” “estimate,” “target,”
“may,” “project,” “guidance,” “intend,” “plan,” “believe” and other
words and terms of similar meaning and expression in connection
with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such
differences include risks relating to the commercial success of our
digital inhalers portfolio; our ability to successfully compete in
the marketplace, including our ability to develop and commercialize
biopharmaceutical products, competition for our specialty products,
including AUSTEDO®, AJOVY® and COPAXONE®; our ability to achieve
expected results from investments in our product pipeline, our
ability to develop and commercialize additional pharmaceutical
products, and the effectiveness of our patents and other measures
to protect our intellectual property rights; our substantial
indebtedness; our business and operations in general, including
uncertainty regarding the COVID-19 pandemic and its impact on our
business, financial condition, operations, cash flows, and
liquidity and on the economy in general, our ability to
successfully execute and maintain the activities and efforts
related to the measures we have taken or may take in response to
the COVID-19 pandemic and associated costs therewith, costs and
delays resulting from the extensive pharmaceutical regulation to
which we are subject or delays in governmental processing time due
to travel and work restrictions caused by the COVID-19 pandemic;
compliance, regulatory and litigation matters, including failure to
comply with complex legal and regulatory environments; other
financial and economic risks; and other factors discussed in our
Annual Report on Form 10-K for the year ended December 31, 2020,
including in the section captioned “Risk Factors.” Forward-looking
statements speak only as of the date on which they are made, and we
assume no obligation to update or revise any forward-looking
statements or other information contained herein, whether as a
result of new information, future events or otherwise. You are
cautioned not to put undue reliance on these forward-looking
_______________________________ 1 Lavorini F. The challenge of
delivering therapeutic aerosols to asthma patients. ISRN Allergy.
2013;2013:102418. Published 2013 Aug 5. 2 Lee LK, Ramakrishnan K,
Safioti G, Ariely R, Schatz M. Asthma control is associated with
economic outcomes, work productivity and health-related quality of
life in patients with asthma. BMJ Open Respir Res.
2020;7(1):e000534. 3 Melani AS, Bonavia M, Cilenti V, et al.
Inhaler mishandling remains common in real life and is associated
with reduced disease control [published correction appears in
Respir Med. 2012 May;106(5):757. 4 Teva data on file. Survey Data.
2021. 5 Teva data on file. Survey Data. 2021. 6 Centers for Disease
Control and Prevention.
Accessed on September 8, 2021. 7 COPD National Action Plan.
Accessed on September 8, 2021. 8 Kaplan A, Price D. Matching
Inhaler Devices with Patients: The Role of the Primary Care
Physician. Can Respir J. 2018;2018:9473051. Published May 23, 2018.
9 Teva data on file. Survey Data. 2021. 10 Teva data on file.
Survey Data. 2021. 11 Jenkins et al. Reliever salbutamol use as a
measure of exacerbation risk in chronic obstructive pulmonary
disease. BMC Pulmonary Medicine. 2015;15:97. 12 Expert Panel
Working Group of the National Heart, Lung, and Blood Institute
(NHLBI) administered and coordinated National Asthma Education and
Prevention Program Coordinating Committee (NAEPPCC), Cloutier MM,
Baptist AP, et al. 2020 Focused Updates to the Asthma Management
Guidelines: A Report from the National Asthma Education and
Prevention Program Coordinating Committee Expert Panel Working
Group [published correction appears in J Allergy Clin Immunol. 2021
Apr;147(4):1528-1530]. J Allergy Clin Immunol.
2020;146(6):1217-1270. 13 Gruffydd-Jones K, Hansen K. Working for
Better Asthma Control: How Can We Improve the Dialogue Between
Patients and Healthcare Professionals?. Adv Ther. 2020;37(1):1-9.
14 Centers for Disease Control and Prevention. Most Recent Asthma
Accessed on August 24, 2021. 15 Centers for Disease Control and
Prevention. What is Chronic obstructive pulmonary disease.
www.cdc.gov/copd/index.html. Accessed on August 24, 2021. 16
Centers for Disease Control and Prevention. Uncontrolled Asthma
among Persons with Current Asthma.
on August 24, 2021. 17 COPD National Action Plan.
Accessed on September 8, 2021. 18 Melani AS, Bonavia M, Cilenti V,
et al. Inhaler mishandling remains common in real life and is
associated with reduced disease control [published correction
appears in Respir Med. 2012 May;106(5):757.] 19 Sulaiman I, Cushen
B, Greene G, et al. Objective Assessment of Adherence to Inhalers
by Patients with Chronic Obstructive Pulmonary Disease [published
correction appears in Am J Respir Crit Care Med. 2017 May
15;195(10):1407]. Am J Respir Crit Care Med.
2017;195(10):1333-1343. 20 Restrepo RD, Alvarez, MT, Wittnebel LD,
et al. Medication adherence issues in patients treated for COPD.
Int J Chron Obstruct Pulmon Dis. 2008;3(3):371-374. 21 Sanchis J,
Gich I, Pedersen S; Aerosol Drug Management Improvement Team
(ADMIT). Systematic Review of Errors in Inhaler Use: Has Patient
Technique Improved Over Time? Chest. 2016;150(2):394-406. 22 Teva
data on file. Survey Data. 2021. 23 Unni E, Gabriel S, Ariely R. A
review of the use and effectiveness of digital health technologies
in patients with asthma. Ann Allergy Asthma Immunol.
2018;121(6):680-691.e1. 24 Larsson, K., Kankaanranta, H., Janson,
C. et al. Bringing asthma care into the twenty-first century. NPJ
Prim. Care Respir. Med. 30, 25 (2020).
version on businesswire.com: https://www.businesswire.com/news/home/20210930005040/en/
IR United States Kevin C. Mannix, (215) 591-8912
Yael Ashman, 972 (3) 914-8262
PR United States Doris Li, (973) 265-3752 Yonatan
Beker, (973) 917-0851
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Oct 2021 to Nov 2021
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Nov 2020 to Nov 2021